title: Reply: Weight-Loss Effect on FVC in Nintedanib Idiopathic Pulmonary Fibrosis Trials?
authors.affiliation: 1 University of Southampton Southampton, United Kingdom.
authors.forename: Luca
authors.initials: L
authors.lastname: Richeldi
authors.affiliation: 2 Boehringer Ingelheim France S.A.S. Reims, France.
authors.forename: Florence
authors.initials: F
authors.lastname: Le Maulf
authors.affiliation: 3 Boehringer Ingelheim Pharmaceuticals Inc. Ridgefield, Connecticut.
authors.forename: Rozsa
authors.initials: R
authors.lastname: Schlenker-Herceg
authors.affiliation: 4 University of California, San Francisco San Francisco, California.
authors.forename: Harold R
authors.initials: HR
authors.lastname: Collard
mesh_terms: D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000188:drug therapy*; D007211:Indoles / Q000008:administration & dosage*; D008297:Male; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*
chemical_list: D004791:Enzyme Inhibitors; D007211:Indoles; D047428:Protein Kinase Inhibitors